Entering a new treatment age for mucopolysaccharidosis VI disease: A search for better markers of disease progression and response to treatment

Jornal de Pediatria

Volumn 84, Issue 2, 2008, Pages 103-106

  Harmatz, Paul ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATAN SULFATE; GALSULFASE; N ACETYLGALACTOSAMINE; PLACEBO;

CLIMBING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE FUNCTION; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; JOINT MOBILITY; MAROTEAUX LAMY SYNDROME; NONHUMAN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SKELETON MALFORMATION; TASK PERFORMANCE; TREATMENT RESPONSE; WALKING;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; MUCOPOLYSACCHARIDOSIS VI; SEVERITY OF ILLNESS INDEX;

EID: 43049112462     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/jped.1768     Document Type: Editorial

References (20)

1. Neufeld EF, Muenzer J. The mucopolysaccharidosis. In: Scriver CR, Beandet AL, Sly S, Valle D, Childs B, Kinzler KW, Volgesltein B, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 2001. p. 3421 52.
2. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics. 2007;120:405-18.
3. Herskhovitz E, Young E, Rainer J, Hall CM, Lidchi V, Chong K, et al. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up. J Inherit Metab Dis. 1999;22:50-62.
4. Lange MC, Teive HA, Troiano AR, Bitencourt M, Funke VA, Setúbal DC, et al. Bone marrow transplantation in patients with storage diseases: a developing country experience. Arq Neuropsiquiatr. 2006;64:1-4.
5. Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, et al.; MPS VI Phase 3 Study Group. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006; 148:533-9.
6. Harmatz P, Whitley CB, Waber L, Pais R, Steiner R, Plecko B, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr. 2004;144:574-80.
7. Harmatz P, Ketteridge D, Giugliani R, Guffon N, Teles EL, Miranda MC, et al.; MPS VI Study Group. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005;115:e681-9.
8. Cardoso-Santos A, Azevedo AC, Fagondes S, Burin MG, Giugliani R, Schwartz IV. Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): assessment of joint mobility and grip and pinch strength. J Pediatr (Rio J). 2008;84(2):130-5
9. Crawley A, Ramsay SL, Byers S, Hopwood J, Meikle PJ. Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry. Pediatr Res. 2004;55:585-91.
10. Fuller M, Meikle PJ, Hopwood JJ. Glycosaminoglycan degradation fragments in mucopolysaccharidosis I. Glycobiology. 2004;14:443-50.
11. Fuller M, Brooks DA, Evangelista M, Hein LK, Hopwood JJ, Meikle PJ. Prediction of neuropathology in mucopolysaccharidosis I patients. Mol Genet Metab. 1005;84:18-24.
12. Randall DR, Sinclair GB, Colobong KE, Hetty E, Clarke LA.Heparin cofactor II-thrombin complex in MPS I: a biomarker of MPS disease. Mol Genet Metab. 2006;88:235-43.
13. Swiedler SJ, Beck M, Bajbouj M, Giugliani R, Schwartz I, Harmatz P, et al. Threshold effect of urinary glycosaminoglycans and thewalk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A. 2005;134:144-50.
14. Byers S, Nuttall JD, Crawley AC, Hopwood JJ, Smith K, Fazzalari NL. Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI. Bone. 1997;21:425-31.
15. Crawley AC, Niedzielski KH, Isaac EL, Davey RC, Byers S, Hopwood JJ. Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J Clin Invest. 1997;99:651-62.
16. Auclair D, Hopwood JJ, Brooks DA, Lemontt JF, Crawley AC. Replacement therapy in Mucopolysaccharidosis type VI: advantages of early onset of therapy. Mol Genet Metab. 2003;78:163-74.
17. McGill JJ, Inwood AC, Coman DJ, Lipke ML, Skinner J, Morris B. Enzyme replacement therapy for MPS VI with recombinant human N-acetylgalactosamine 4-sulphatase (rhASB) from 8 weeks of age - a sibling control study. J Inherit Metab Dis. 2006;29 Suppl 1:65.
18. Turecek F, Scott CR, Gelb MH. Tandemmass spectrometry in the detection of inborn errors of metabolism for newborn screening. Methods Mol Biol. 2007;359:143-57.
19. Hein LK, Meikle PJ, Dean CJ, Bockmann MR, Auclair D, Hopwood JJ, et al. Development of an assay for the detection of mucopolysaccharidosis type VI patients using dried blood-spots. Clin Chim Acta. 2005;353:67-74.
20. Meikle PJ, Grasby DJ, Dean CJ, Lang DL, Bockmann M, Whittle AM, et al. Newborn screening for lysosomal storage disorders. Mol Genet Metab. 2006;88:307-14.